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PURPOSE. This study evaluated a new subretinal method for delivery of human or pig umbilical
tissue–derived cells (hUTC or pUTC, respectively) using a novel subretinal injection cannula
and suprachoroidal approach in Göttingen minipig eyes. hUTC (palucorcel) are currently
under development for treating geographic atrophy in humans.
METHODS. Twenty-four Göttingen minipigs (divided into eight groups) were subretinally
administered palucorcel, pUTC, or vehicle. In some cases, fluorescently labeled cells and
vehicle were administered. Conjunctival cutdown and sclerotomy were performed, then a
flexible cannula containing a microneedle was inserted and advanced into the suprachoroidal
space. The microneedle was deployed and visualized; 50 lL cells (target concentration, 11.2
3 106 cells/mL [560,000 cells/eye]) or vehicle was injected subretinally. Safety outcomes
were evaluated.
RESULTS. For all animals, cells and vehicle were successfully administered. Labeled cells or
fluorescent vehicle were contained in the subretinal bleb, without leakage into the vitreous.
No retinal detachment or vitreous traction band was identified by ophthalmologic
examination. At all time points, observed microscopic changes were attributable to
experimental procedures. On histopathology immediately after injection, localized retinal
detachments were seen, along with focal retinal, choroidal, and/or scleral discontinuities. A
moderate inflammatory response was seen in a limited number of animals. In the allogeneic
setting, no antibody responses were detectable. Anti-human UTC antibodies were detected in
the xenogeneic setting.
CONCLUSIONS. Palucorcel, pUTC, and vehicle were successfully administered to Göttingen
minipigs using a novel subretinal injection cannula via a suprachoroidal surgical approach,
with no significant adverse events; therefore, this technique appears to be feasible for further
clinical development.
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AMD is a multifactorial, degenerative disease that is a leadingcause of blindness in industrialized countries in people 55
years of age or older.1–4 The early and intermediate stages of the
disease are characterized by the accumulation of drusen and a
slow loss of the choriocapillaris.5–7 Initially, both stages are
associated with minimal impairment of visual acuity.3,8,9
However, in advanced AMD, loss of vision can be caused by
either exudative neovascular (‘‘wet’’) AMD or geographic
atrophy (GA).8 GA, which comprises 35% to 40% of all cases
of advanced AMD, is a slowly progressive disease, characterized
by loss of the RPE cells, retinal photoreceptors, and chorio-
capillaris, and is the cause of 20% of all cases of legal blindness
in the United States.10–11 The appearance and growth of drusen
deposits are prognostic indicators for GA, and the median time
to develop central GA after any GA diagnosis is 2.5 years.12–14
The Age Related Eye Disease Study (AREDS) and Beaver Dam
Eye Study demonstrated that the highest likelihood of
developing GA is found in eyes with multiple large drusen
(>125 lm) and in those with soft indistinct drusen, particularly
when associated with macular pigmentary abnormalities.12,14
Despite the high prevalence and burden of dry AMD, there are
no therapies currently available that are effective in delaying or
preventing vision loss related to GA.15,16
Palucorcel (CNTO 2476) is currently being evaluated as a
novel cell-based therapy for the treatment of GA secondary to
AMD. Palucorcel is composed of human umbilical cord tissue–
derived cells (hUTC),17 and the nature and characterization of
these cells has been reported previously.18 The cells are
supplied in a proprietary cryopreserved formulation that is
thawed shortly before use according to the manufacturer’s
instructions. Subretinal administration of palucorcel was
associated with preservation of visual function in a rat model
of retinal degeneration.17 Subsequent in vitro studies showed
that palucorcel was capable of rescuing RPE phagocytic
dysfunction, promoting excitatory synaptic connectivity, en-
hancing neuronal survival, and enhancing neurite outgrowth
via paracrine signaling pathways.19,20 A recent phase 1/2a study
evaluated the administration of palucorcel in 35 adults, 50 years
of age and older, with bilateral GA secondary to AMD. A
microcatheter delivery system (iTrack 275; iScience, Inc.,
Menlo Park, CA, USA) was used in conjunction with an ab
externo surgical approach to access the subretinal space.18
Palucorcel was well tolerated when delivered without retinal
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perforation. There was no clinical evidence of an immune
response, cell rejection, or tumor formation.18 The low
humoral immunogenicity of palucorcel observed in the phase
1/2a study was supported by previous preclinical studies
showing that a single injection of pig umbilical tissue–derived
cells (pUTC) in minipigs was not associated with a detectable
immune response.21,22 Although palucorcel was well tolerated
in the phase 1/2a study, the ab externo surgical approach
required to access the subretinal space with the microcatheter
delivery system was associated with a high rate of retinal
perforations (13/35 operated subjects) and retinal detachments
(6/35 operated subjects).18 In another phase 1 study in
subjects with retinitis pigmentosa, inadvertent seeding into
the vitreous cavity, while injecting palucorcel into the
subretinal space via a transvitreal approach, was associated
with retinal detachment, as well as the formation of epiretinal
membranes.23 The occurrence of retinal detachments and
perforations in both early studies highlighted the need to
develop a safer targeted surgical technique to deliver
palucorcel into the subretinal space.
In the present study, we evaluated a novel method for the
subretinal delivery of balanced salt solution (BSSþ; Alcon
Laboratories, Inc., Fort Worth, TX, USA), as well as both
palucorcel and pUTC, using a novel subretinal injection
cannula via the suprachoroidal space in minipigs. Features of
this device include a flexible cannula with an advanceable
microneedle for accessing the subretinal space (Fig. 1). This
approach was designed to make use of the suprachoroidal
space to deliver palucorcel at a specific site in the subretinal
space with minimal trauma to ocular tissues while minimizing
the egress of cells. The objectives of this study included the
evaluation and identification of potential adverse effects
associated with the use of the novel subretinal injection
cannula; an assessment of the suprachoroidal surgical ap-
proach to deliver palucorcel subretinally; and the documenta-
tion of the cell injection procedure, device, and surgical
performance in the preclinical setting. Additional objectives
included an evaluation of the surgical healing time; character-
ization of postdosing disposition of administered fluorescent
vehicle and carboxyfluorescein diacetate succinimidyl ester
(CFSE)–labeled cells; and the identification of potential
humoral immune responses as induced by the subretinal
placement of either palucorcel or the pig analog, pUTC.
METHODS
This study was performed in accordance with the Organization
for Economic Cooperation and Development Principles of
Good Laboratory Practice and as accepted by local regulatory
authorities. This study was conducted at the Charles River
Laboratories Montreal ULC Senneville Site (Senneville, QC,
Canada). The Test Facility Quality Assurance Program moni-
tored the study to assure the facilities, equipment, personnel,
methods, practices, records, and controls conformed to Good
Laboratory Practice regulations. Animal use was in adherence
with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research, and the protocol was reviewed by an
animal care and use committee.
Subretinal Injection Cannula
The subretinal injection cannula used in this study has a
number of unique design features to improve the safety of
subretinal cell delivery via a suprachoroidal approach com-
pared to previous surgical approaches or devices used to
access the subretinal space. The flexible cannula conforms to
the curvature of the eye and is intended to cannulate the
suprachoroidal space, reducing the risk of choroidal hemor-
rhage when entering the suprachoroidal space. The advance-
able microneedle housed within the cannula is intended to
penetrate the choroid to provide access to the subretinal space
without disruption or penetration of the retina. A knob on the
handle allows for controlled advancement of the microneedle,
and a third arm-positioning tool is used to stabilize the cannula
during insertion into the suprachoroidal space. During the
surgical procedure, a BSSþ entry bleb is created prior to cell
delivery. The device fluid path allows for BSSþ and cell delivery
without mixing, and the BSSþ entry bleb allows for the
procedure to be aborted before cells are delivered if retinal
penetration is observed.
Test Articles
Palucorcel was derived from umbilical cord tissue of a single
donor as described previously.17,18 Palucorcel was developed
in compliance with all relevant regulations, including donor
consent. Briefly, after digestion with enzymes, a homogenous
subpopulation of umbilical cord tissue cells was isolated,
cultured, and used to derive a Master Cell Bank. These cells
were then prepared as a frozen suspension in CryoStor-SCO
4B/BSS (CS-SCO 4B/BSS, proprietary formulation, Janssen R&D,
Spring House, PA, USA). Palucorcel was stored in liquid
nitrogen vapor phase at temperatures below 1208C until
ready for use.
The pUTC were isolated and expanded in a manner similar
to palucorcel from pigs that were recognized by the United
States Department of Agriculture as free of brucellosis,
pseudorabies, transmissible gastroenteritis, and porcine repro-
ductive and respiratory syndrome. Piglets used for deriving
pUTC were vaccinated against Mycoplasma hypopneumo-
niae, Pasteurella multocida, Bordetella bronchiseptica, and
Erysipelothrix rhusiopathiae. Adult pigs were vaccinated
against E. rhusiopathiae, Leptospira, and parvovirus. Cells
were formulated in 90% (vol/vol) fetal bovine serum (FBS; GE
Healthcare, Logan, UT, USA) and 10% (vol/vol) dimethylsulf-
oxide (Sigma-Aldrich Corp., St. Louis, MO, USA) and cryopre-
served in liquid nitrogen vapor phase at temperatures below
1208C.
Palucorcel and pUTC dose formulations were prepared
using aseptic technique. Vials of cryopreserved cells were
thawed in a water bath at 378C. Shortly after, palucorcel was
administered directly to the subretinal space. For pUTC, cells
FIGURE 1. Picture of the subretinal injection cannula device used for
cell delivery to the subretinal space of the eye.
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were washed twice in BSS and resuspended in CS-SCO 4B/BSS.
Cell counts were then obtained on transferred aliquots of
palucorcel and pUTC to ensure that the viable cell concentra-
tions were ‡70% in order to meet dosage level requirements
for administration.
Some vials of palucorcel and pUTC were labeled with cCFSE
using a kit (Vybrant CFDA SE Cell Tracker Kit; Molecular
Probes, Inc., Eugene, OR, USA). Briefly, cells were thawed at
378C in a water bath for 2 minutes. The pUTC were washed
twice in BSS and resuspended in CS-SCO 4B/BSS. Palucorcel
was used directly after thaw. Each cell type (330 lL) was
combined with 670 lL 378C 1X Dulbecco’s phosphate buffered
saline (DPBS; Life Technologies, Carlsbad, CA, USA). Cells were
subsequently incubated with 0.5 lL 5 mM CFSE for 15 minutes
in the dark. The reaction was quenched by adding 1 mL 378C
FBS. Cells were washed twice with 1X DPBS using centrifu-
gation. Cellular pellets were resuspended in 10% FBS prepared
in 1X DPBS such that the target concentration was 11.2 3 106
cells/mL (560,000 cells/eye).
Animals and Treatment Administration
Male Göttingen minipigs were obtained from Marshall Bio-
Resources (North Rose, NY, USA). Animals were between 9 and
10.5 months old and weighed 12.9 to 17.6 kg at the start of the
study. Animals were assigned to treatment groups by a
stratified randomization scheme designed to achieve similar
group body weights. Animals were single-housed in stainless
steel cages with an automatic watering valve and had access to
a standard certified commercial laboratory diet (Harlan Teklad
Miniswine Diet 8753; Harlan Laboratories, Inc., Madison, WI,
USA) twice daily except during specified study procedures.
A total of 24 Göttingen minipigs were divided into eight
equal treatment groups. In preparation for dose administration,
a topical antibiotic (0.3% tobramycin) was applied to both eyes
twice on the day before and the day after subretinal injection.
Tobramycin was also applied to some eyes 2 days before dose
administration. Animals were fasted overnight or for an
appropriate period before the dosing procedure and anesthe-
tized via intramuscular injection of a sedative cocktail of
ketamine (22 mg/kg), glycopyrrolate (0.01 mg/kg), and
acepromazine (1.1 mg/kg). An isoflurane/oxygen mix was
administered to the animals via an endotracheal tube during
the procedure. The conjunctivas were then flushed with
benzalkonium chloride (Zephiran; Sanofi-Aventis US, LLC,
Bridgewater, NJ, USA) diluted in sterile water to 1:10,000
(vol/vol). Topical anesthetic drops (proparacaine) were ap-
plied, along with tropicamide 1% and/or cyclopentolate 1%
mydriatic drops (Cyclogyl; Alcon Laboratories, Inc.) to obtain
suitable pupil dilation. Animals received intravenous lactated
Ringer’s solution (10 mL/kg/h) during the dosing procedure to
aid in recovery from anesthesia.
On day 1, a single subretinal injection of vehicle (CS-SCO
4B/BSS; groups 3 and 6), palucorcel (target concentration, 11.2
3 106 cells/mL [targeted dose, 5.6 3 105 cells] in CS-SCO 4B/
BSS; groups 1, 4, and 7), or pUTC (target concentration 11.2 3
106 cells/mL [targeted dose, 5.6 3 105 cells] in CS-SCO 4B/BSS;
groups 2, 5, and 8) was administered in a volume of 50 lL in
the right (treated) eye (Table 1). These injections were
preceded by injection of a small volume of BSSþ for bleb
formation. For groups 1 and 2, palucorcel and pUTC,
respectively, were fluorescently labeled with CFSE before
administration. Animals in group 2 received vehicle CS-SSCO
4B/BSS containing fluorescein (FA) and indocyanine green
(ICG) in the left eye. For all other groups, the left eye was
untreated and did not undergo surgical procedures. The dose
of palucorcel used in this study was based on the highest dose
used in prior clinical studies.18 An equivalent dose of pUTC
was used to facilitate comparison of potential effects in the
xenogeneic and allogeneic setting.
Animals in groups 1 and 2 were terminated on the day of
surgery; those in groups 3 to 5 were terminated at month 1
(day 30); and those in groups 6 to 8 were terminated at month
3 (day 92; Table 1).
Suprachoroidal Surgical Approach and Subretinal
Injection Cannula
All surgeries were performed by a single vitreoretinal surgeon.
The conjunctiva was opened, and the underlying sclera was
freed from any overlying connective tissue. A marker was used
to indicate the position of retaining sutures (6-0 Vicryl sutures;
Ethicon, Inc., Somerville, NJ, USA) and the position and size of
a sclerotomy, parallel but located 8 to 9 mm posteriorly to the
limbus. The sclerotomy was created using a crescent knife, and
the remaining scleral fibers were removed with a Sinsky hook.
The diameter was adjusted to allow for passage of the cannula
while providing a snug fit. The subretinal injection cannula was
passed under the retaining sutures and advanced tangential to
the eye through the sclerotomy, approximately 3 to 5 mm into
the suprachoroidal space. Once in position, the cannula was
sutured to the surface of the sclera to prevent unwanted
movement of the cannula. Using indirect ophthalmoscopy to
visualize the cannula tip, the microneedle was carefully
advanced into the subretinal space. A small BSSþ entry bleb
was created to confirm that the microneedle tip was in the
subretinal space. This was followed by the administration of
cells (560,000 cells/eye) or vehicle in a 50-lL volume forming a
TABLE 1. Dosing Groups
Group
Target Concentration, Cells/mL*
Scheduled EuthanasiaLeft Eye Right Eye
1 Untreated control 11.2 3 106 palucorcel labeled with CFSE† Day 1
2 Vehicle‡ labeled with FA (1 mg/mL) and ICG (0.05 mg/mL) 11.2 3 106 pUTC labeled with CFSE† Day 1
3 Untreated control Vehicle‡ Month 1 (day 30)
4 Untreated control 11.2 3 106 palucorcel† Month 1 (day 30)
5 Untreated control 11.2 3 106 pUTC† Month 1 (day 30)
6 Untreated control Vehicle‡ Month 3 (day 92)
7 Untreated control 11.2 3 106 palucorcel† Month 3 (day 92)
8 Untreated control 11.2 3 106 pUTC† Month 3 (day 92)
ICG, indocyanin green.
* All doses were administered as a single dose of 50 lL per eye.
† Target dose, 5.6 3 105 cells/eye.
‡ CS-SCO 4B/BSS.
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small bleb around the microneedle tip (Fig. 2). The micronee-
dle was then retracted, and the cannula was removed. The
sclerotomy and conjunctiva were closed using Vicryl sutures.
Study Assessments
Minipigs first underwent routine ophthalmic examinations
using a handheld slit lamp. Eyes were then dilated with 1%
tropicamide and examined using an indirect ophthalmoscope.
All ophthalmic examinations were performed by a trained
ophthalmic veterinarian. FA and ICG angiography using a
scanning laser ophthalmoscope (Spectralis; Heidelberg Engi-
neering, Heidelberg, Germany) and electroretinography (ERG)
(LKC UTAS-E-4000 with EMWin software) were performed at
predetermined time points, as described below. In eyes that
had received CFSE-labeled cells or vehicle with a fluorescent
dye, fluorescence was measured using the blue filter on the
Spectralis imaging system on the day of injection. Ophthalmic
examinations were performed once before treatment; on days
3, 7, and 15; approximately 1 month after surgery; and monthly
thereafter. Fundus imaging was performed once before and
immediately following the surgical procedure on day 1 for
animals who received fluorescently labeled cells or vehicle
with fluorescent dye. FA and ICG angiography were performed
once before treatment, at 1 month after dosing, and before
necropsy. No postdose angiography was performed on animals
euthanized on day 1. ERG was performed once before
treatment and before necropsy for all animals except those
euthanized on day 1. Following necropsy, histopathology was
performed on each eye by a board-certified veterinary
pathologist.
Intraoperative assessments included the device’s ability to
access the suprachoroidal space, the ease of insertion and
advancement into this space, the microneedle’s ability and ease
of accessing the subretinal space, and the microneedle’s ability
to deliver the product. These outcomes were recorded during
or directly following the procedure using a formalized
questionnaire. Any complications, such as a hemorrhage in
any ocular compartment, retinal perforation and/or delivery of
vehicle or cells to the vitreous, leakage of injected formulation
after microneedle withdrawal, or collapse of the bleb following
the removal of the cannula, were also recorded. Routine
monitoring and safety assessments, including body weights,
food consumption, and clinical pathology parameters (hema-
tology, coagulation, clinical chemistry) were evaluated based
on clinical observations and blood samples. Serum was
collected once before treatment (on all animals); during weeks
1 and 2; and at months 1, 2, and 3 (depending on scheduled
euthanasia) and was tested for the presence of IgG antibodies
against palucorcel or IgG antibodies against pUTC using flow
cytometry.
Detection of Anti-hUTC or Anti-pUTC IgG
Antibodies in Serum
Serum samples were analyzed for the detection of anti-hUTC or
anti-pUTC IgG antibodies using a flow cytometry method.
Briefly, hUTC or pUTC were cultured to confluence and
subsequently activated by addition of 25 ng/mL human IFN-c
(Invitrogen, Carlsbad, CA, USA) or 80 ng/mL porcine IFN-c
(R&D Systems, Inc., Minneapolis, MN, USA), respectively, for
48 hours. Cells were harvested and then treated with normal
minipig serum (NMS), undiluted test samples, or undiluted
positive controls (porcine serum obtained from pigs immu-
nized with pUTC or hUTC). Fluorochrome-labeled antibodies
against pig IgG antibodies were used as a secondary reagent to
allow detection of pig anti-pUTC or pig anti-hUTC IgG
antibodies by flow cytometry. Negative controls (secondary
antibody only) were used to set the flow cytometer (FACSCa-
libur; Beckton-Dickinson, Franklin Lakes, NJ, USA) voltages by
setting the peak geometric mean fluorescence (GMF) between
100 and 101 (log histogram), while the NMS control
represented background signal. A sample was considered
positive if that sample’s GMFSample/GMFNegative ratio was
above the set cut-point. The pre- and all postdose samples from
each animal were analyzed in the same experiment on IFN-c–
activated hUTC and pUTC cells. The cut-point was established
to be 1.013 for anti-hUTC IgG and 0.960 for anti-pUTC IgG.
Postdose samples that were found to be positive based on the
cut-point were further evaluated by comparing their GMF
against the GMF of their respective predose sample (GMFPost-
dose/GMFPredose) to see if an increase in anti-hUTC or anti-
FIGURE 2. Depiction of the insertion and delivery of palucorcel to the subretinal space. (A) Insertion of the cannula (through suture loops) into the
suprachoroidal space via a sclerotomy. (B) Fundus view of the cannula positioned within the suprachoroidal space (visible under the retina) with
cells and vehicle being dispensed (depicted as green) into the subretinal space approximately two disc diameters away from the optic nerve. (C)
Microneedle penetrating through the choroid to form a subretinal bleb.
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pUTC IgG was observed during the dosing phase when
compared to predose levels. A postdose sample that showed an
increase greater than 30% (GMFPostdose /GMFPredose ratio >
1.3) compared to the corresponding predose sample was
considered as potentially containing anti-hUTC or anti-pUTC
IgG antibodies.
Terminal Procedures
Animals were subjected to a complete necropsy examination.
Eyes and optic nerves were collected and preserved in
Davidson’s fixative. The eyelids, extraocular muscle, and
nictitating membrane (bilateral) were preserved in 10% neutral
buffered formalin. Tissues were embedded in paraffin,
sectioned, mounted on glass slides, and stained with hematox-
ylin and eosin. For each eye, at least two slides were prepared
for sagittal sections from each of the following locations: the
sclerotomy incision site, the catheter tract, the bleb areas (if
visible), and the optic nerves. Histopathological evaluation was
performed by a board-certified veterinary pathologist at
Charles River Labs in Montreal. Select images were captured
at the discretion of the study pathologist with the Aperio
Digital Image Capture System (Leica Biosystems, Buffalo Grove,
IL, USA).
RESULTS
Palucorcel Exposure and Fundus Imaging
Palucorcel, pUTC, and vehicle were successfully administered
using the subretinal injection cannula and suprachoroidal
surgical procedure in all animals. The targeted cell concentra-
tion of palucorcel and pUTC across all dose groups was 11.2 3
106 cells/mL (560,000 cells/eye). Actual concentrations of
palucorcel delivered ranged from 7.93 3 106 to 11.98 3 106
cells/mL. Actual concentrations of pUTC delivered ranged from
6.88 3 106 to 14.68 3 106 cells/mL.
Immediately post dose, CFSE-labeled palucorcel was clearly
visible as multifocal pinpoints of hyperfluorescence located in
the bleb in autofluorescence fundus images (example shown in
Fig. 3A). The fluorescent vehicle was clearly visible as a
discrete area of hyperfluorescence in the bleb area during
fundus imaging (example shown in Fig. 3B). Based on fundus
imaging, no leakage of cells or vehicle into the vitreous was
observed.
Surgical Observations
In all operated eyes, the procedure was performed as planned
without any device failure. Cannula insertion into the
suprachoroidal space was rated as very easy or easy for the
majority of operated eyes (23/27). Possible retinal perforations
were reported in four of 27 operated eyes, and partial bleb
collapse was noted in six of 27 operated eyes. A subretinal
hemorrhage was noted in one of the 27 operated eyes, but in
no case did a choroidal or subretinal hemorrhage prevent
successful delivery (Table 2).
Clinical Observations
As expected, there were no unscheduled deaths during the
study. Following surgery, there were no clinical signs (e.g.,
changes in body weight, food consumption, clinical pathology
parameters) that were considered related to palucorcel or
pUTC. The observed clinical signs were related to the
experimental procedures. Ocular clinical signs included ocular
discharge, conjunctival hyperemia, and periorbital swelling, as
well as periorbital skin staining and scabbing. These clinical
signs generally resolved within the first month, although
conjunctival hyperemia persisted through day 52 in animals
euthanized at month 3. Hyperemia was not associated with any
signs of intraocular inflammation.
Ophthalmic Observations
Ophthalmic observations for eyes administered with CS-SCO
vehicle, palucorcel, or pUTC are summarized in Supplemen-
tary Table S1. Diffuse hyperemia, hemorrhage, and swelling
resulting from the surgery improved significantly over the first
few weeks. Minor corneal findings (focal or diffuse opacities
FIGURE 3. Autofluorescence imaging of (A) CFSE-labeled palucorcel
within the subretinal bleb immediately post surgery and (B) cell
vehicle containing 1 mg/mL FA and 0.05 mg/mL ICG illuminating the
region of the subretinal bleb.
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and superficial vascularization) related to the experimental
procedures improved or resolved during the initial postoper-
ative month, although slight focal corneal opacities remained
present in two eyes at 3 months post dose. Minor retinal
changes (focal grayish retinal haze, irregular retina/choroid
pigmentation, focal/multifocal hemorrhages, and focal retina/
choroid opacities) related to the experimental procedures
improved or resolved during the first postoperative month.
Slight to moderate focal retinal elevations caused by bleb
formation during the dosing procedure were observed at day 3
in all vehicle-treated eyes and resolved within 1 week.
Similar to vehicle, subretinal administration of palucorcel or
pUTC caused minor observable changes. There was no sign of
ocular inflammation. At the site of injection, the following
minor alterations were observed: slight to moderate grayish
cell-like retinal opacities suggestive of cellular aggregates that
were present in the subretinal space of all palucorcel-treated
eyes and most pUTC-treated eyes. These grayish opacities,
which were not present in vehicle-treated eyes, resolved
within 1 to 2 months after dosing. Slight to moderate focal
retinal elevations caused by bleb formation were observed on
day 3 in eyes receiving palucorcel or pUTC. These had resolved
by 1 month. Similar focal retinal elevations were observed in
vehicle-treated eyes, but resolved more rapidly. At the cannula
entry site into the suprachoroidal space, a small patch of bare
sclera was present that was devoid of choroidal vasculature.
This was not associated with any retinal detachments or
vitreous traction bands (by ophthalmic observation) with
vehicle, palucorcel, or pUTC administration. No abnormalities
were noted in the neighboring tissues.
Angiography
In four animals that received palucorcel, focal changes were
observed on FA and ICG angiography in the area of subretinal
delivery. No dye leakage was noted from either the retinal or
choroidal vasculature. At the 1-month angiogram, one animal
had focal areas of FA hyperfluorescence within the area
corresponding to the surgically induced subretinal bleb. Two
focal areas of hypofluorescence were visible on ICG angio-
grams in the same vicinity for that animal. On 3-month
angiograms, focal areas of FA hypofluorescence and/or hyper-
fluorescence were present in the superior or superotemporal
region of the fundus of two animals (both administered with
palucorcel) in the area of the subretinal bleb. Focal hypofluor-
escent areas were present in the same locations on ICG
angiograms and may indicate the subretinal injection site. In
addition, tortuous small vessels were present at one hypo-
fluorescent site for one of the two animals with focal
hypofluorescence and/or hyperfluorescence on FA angiograms
at month 3. Similar findings were observed in one animal
administered with pUTC at months 1 and 3.
Electroretinography
No changes in scotopic or photopic ERG amplitudes and
implicit times were observed in eyes that were administered
with palucorcel or pUTC as compared with eyes treated with
CS-SCO vehicle. At 1 month and 3 months post dose, minor
increases or decreases in average amplitudes and implicit times
were often observed in all treated eyes compared to their
baseline measurements and were considered to be related to
individual variability and/or anesthesia levels (Supplementary
Table S2).
Histopathology
Histopathologic observations in animals euthanized on day 1,
month 1 (day 30), and month 3 (day 92) are summarized in
Table 3. At all time points, some microscopic changes
attributable to the experimental procedures were observed.
On histopathologic examination, animals that were euthanized
immediately after surgery characteristically had a peripheral
retinal detachment at the site of injection; focal discontinuity of
the retina, choroid, and/or sclera; infiltration of the limbus by a
mixed population of inflammatory cells; and subretinal,
subchoroidal, and/or limbus hemorrhage. The retinal detach-
ment observed immediately post dose was limited to a focal
area in the mid to posterior retina and corresponded to the
injection site and the retinal elevations observed in ophthalmic
observation. In some cases, test item cells were noted in the
subretinal space (Fig. 4). Changes in the eyes of all groups of
animals euthanized 1 month post dose included inflammatory
cell infiltration (choroid, sclera, and/or limbus); fibrosis of the
TABLE 2. Summary of Intraoperative Assessment Findings
Group
Euthanized Day 1 Euthanized Month 1 Euthanized Month 3
Intraoperative Assessment Findings,
No. of Eyes Affected Palucorcel Vehicle/pUTC Vehicle Palucorcel UTC Vehicle Palucorcel pUTC
No. of eyes evaluated 3 6 3 3 3 3 3 3
Device accessed the suprachoroidal space 3 6 3 3 3 3 3 3
Cannula perforated the choroid – 1 – – – – – –
Microneedle accessed the subretinal space 3 6 3 3 3 3 3 3
Retinal perforation occurred – 3 – – – – – 1
Due to microneedle – 2 – – – – – 1
Due to cannula – 1 – – – – – –
Hemorrhage prevented subretinal delivery – – – – – – – –
Subretinal hemorrhage – – – – 1 – – –
Product was delivered to the subretinal space 3 6 3 3 3 3 3 3
Product was visible in vitreous after delivery – 1 – – – – – –
Bleb collapsed after device withdrawal – 4 – – 1 1 – –
General device failure – – – – – – –
Ease of cannula insertion into suprachoroidal space
Very easy 2 5 3 2 3 3 3 2
Easy – – – – – – – 1
Somewhat difficult – 1 – – – – – –
Difficult 1 – – 1 – – – –
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sclera; pigmented macrophages in the vitreous chamber,
choroid, and retina; and disorganization of the retina (mainly
the outer nuclear and photoreceptor layers). By 3 months post
dose, microscopic findings included inflammatory cell infiltra-
tion (retina, choroid, and/or sclera), choroid fibrosis or
discontinuity, and disorganization (Fig. 5). Retinal degeneration
or atrophy, following focal discontinuity of the retina, remained
present. In two of three animals that received palucorcel
(xenogeneic) and were euthanized at month 3 (day 92), small
focal retinal granulomas were observed (Fig. 5A). No granulo-
mas were observed in eyes that received pUTC (allogeneic) or
vehicle (Fig. 5B).
Serum Antibody Titers
Subretinal administration of palucorcel in CS-SCO 4B/BSS to
minipigs (xenogeneic setting) resulted in detectable levels of
anti-hUTC IgG antibodies in two of six animals (Supplementary
Table S3). One animal (necropsied on day 30) showed elevated
anti-hUTC IgG levels at week 2 post dosing. The antibody
response continued to persist at month 1. Another animal
(necropsied on day 92) showed no change at month 1 and
elevated anti-hUTC IgG levels at 2 months post dosing that
dropped off at month 3 post dosing. In contrast, subretinal
administration of pUTC to minipigs (allogeneic) resulted in no
detectable levels of anti-pUTC antibodies (Supplementary
Table S4).
DISCUSSION
This study evaluated the safety, tolerability, and clinical
response of a single, subretinal injection of palucorcel or
pUTC through the suprachoroidal space, using a novel
injection cannula. The technology and techniques used in this
novel subretinal delivery procedure were developed with
expert retinal surgeons who helped to create a procedure that
builds off previously known skills and devices. Surgical steps,
TABLE 3. Summary of Microscopic Eye Findings
Microscopic Eye Findings

















Hemorrhage 2 2   1   
Retina detachment 3 2      
Choroid discontinuity  2    1  
Retina discontinuity  2      
Sclera discontinuity  1      
Mixed cell limbus infiltration 1  2 3 3 2  2
Mixed cell sclera infiltration    1    
Mononuclear cell choroid infiltration   2 3   3 1
Mononuclear cell sclera infiltration   1 2  2 2 2
Mononuclear cell retina infiltration       1
Mononuclear cell conjunctiva infiltration       1 
Retina disorganization   1 3 2  3 1
Retina gliosis    1    
Sclera fibrosis     1   
Choroid fibrosis        1
Macrophage aggregation   1   1  
Retina degeneration      1 1 
Retina atrophy      2 1 2
Retina granuloma       2 
FIGURE 4. Palucorcel in the subretinal space with focal retinal detachment 1 day post surgery. IPL, inner plexiform layer; INL, inner nuclear layer;
OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment.
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such as conjunctival peritomy, eye rotation, choroidal expo-
sure via a sclerotomy, and needle puncture of the choroid are
all standard techniques used for decades in retinal detachment
drainage procedures.24 With regard to suprachoroidal cannu-
lation, Olsen and colleagues25 described a microcatheter for
(1) insertion into the suprachoroidal space, (2) advancement to
the macular region, and (3) delivery of a therapeutic product to
the suprachoroidal space. El Rayes and Elborgy26 used
suprachoroidal cannulation to create an internal buckle for
retinal detachments by injecting a long-lasting viscoelastic
through an olive tip cannula. A number of subretinal injection
procedures, particularly in the macular area, have made use of
a transvitreal approach following a pars plana vitrectomy.27–29
While many have used small-gauge nonextendible cannulas,
some (including Komaromy and colleagues30) have proposed
an extendable microneedle for improved subretinal injection.
Nevertheless, subretinal delivery through a transvitreal ap-
proach remains challenging. Delivered product can escape out
of the retinotomy into the vitreous during delivery, during
needle withdrawal, or subsequently, as a stretched retina
regains its original position. In addition, it is difficult to prevent
expansion of the retinotomy during the delivery due to hand
tremor. In the first in-human trial of palucorcel in patients with
retinitis pigmentosa, the subretinal delivery of cells via a
transretinal approach was associated with reflux and the
formation of an epiretinal membrane in some patients.23
Robotic-assisted surgical solutions may mitigate these challeng-
es by providing high positional stability in all primary
directions.31,32 Positional stability also eliminates the need to
proceed quickly with the injection, a requirement of manual
procedures that may limit the applicability of any transvitreal
injection technique in scarred retina. The association of
robotics assistance with smart positioning devices or its
combination with optical coherence tomography can further
increase the precision of such deliveries in the future.
Reaching the subretinal space without breeching the
integrity of the retina would obviate many of these concerns
but requires suprachoroidal access to position the needle in
the appropriate location, followed by advancement of the
needle into the subretinal space.
Previous clinical and preclinical studies showed improve-
ments in visual function when palucorcel was delivered
subretinally.17,18 While delivery of the cell product to the
suprachoroidal space would be surgically easier, the subretinal
space is an immune privilege site compared with all spaces
beyond the RPE, which are not.33 Cell survival would be
decreased with delivery to the suprachoroidal space, and the
possibility of retreatment if needed would be abrogated by the
immune response. In addition, any trophic factors produced by
the suprachoroidally placed cells, along with the cells
themselves, would be rapidly cleared out of the eye through
emissary channels34,35 or would be hindered from reaching the
retina by multiple barriers within the choroid, Bruch’s
membrane, and RPE.36 For these reasons, the subretinal space
was defined as the target for delivery, and the technique
described here was developed to ensure the drug product is
physically deposited adjacent to the target retinal cells.
In order to achieve our goal, a novel suprachoroidal
positioning cannula coupled to a subretinal extension needle
was required. The current procedure and device is novel in its
ability to combine the positioning of a catheter in the
suprachoroidal space with the safe delivery of a biologically
active product to the subretinal space. In the process of
developing the cannula/needle combination, several parame-
ters were considered. These included the following: allowing
the surgeon to safely position the catheter within the
suprachoroidal space at a predetermined position (a rectangu-
lar design); the safe advancement of a microneedle to pierce
through Bruch’s membrane without damaging or perforating
the retina (extension from the distal end of the catheter at an
appropriate angle); and removing the effect of hand tremor
and the need to proceed quickly with the injection.
Dose formulations were successfully administered into the
subretinal space of Göttingen minipigs in 27 out of 27 eyes.
CFSE fluorescently labeled cells or fluorescent vehicle were
immediately visible post dose within the subretinal bleb, and
no leakage of cells or vehicle into the vitreous was observed.
Intraoperative observations generally indicated that the proce-
dure was easy to perform and was associated with a relatively
low rate of retinal perforations in comparison to the previous
ab externo microcatheter-based system. The delivery blebs that
were formed were closely observed. Most of the blebs
remained fully formed when observed immediately after the
procedure, with partial collapse observed in only 6 of 27 blebs.
These collapses were typically present when the removal of
the catheter was more complicated, for example, when the
catheter was torqued during removal. These findings indicate
that a smooth retraction along the same entry path is needed to
prevent bleb collapse. The ophthalmic observation of retinal
elevation in the area of the subretinal injection was observed
and tracked over time, generally decreasing in severity from
moderate at day 3 in some animals to slight or very slight by
day 15, with resolution in all animals by 1 month (Supplemen-
tary Table S1). These intraoperative and ophthalmic exam
findings provide supporting evidence for successful subretinal
cell delivery followed by cell media fluid transport out of the
subretinal space over time. This result on cell media fluid
FIGURE 5. Retinal disorganization and granuloma (day 92) indicative of
a xenogeneic response to palucorcel (A). Granulomas were not
observed in the allogenic setting. Focal disorganization of the retina
and minimal choroid fibrosis observed on day 92 in an animal that
received pUTC (B).
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transport is in agreement with previously described kinetics of
macromolecules injected into the subretinal space.37
Histology performed immediately after dosing showed the
presence of the expected retinal detachment. This histopath-
ologic observation of retinal detachment corresponded to the
ophthalmic observation of retinal elevations. In some eyes,
cells could be observed in the subretinal space but not in the
choroid or suprachoroidal space. At 3 months, in two of three
eyes that received palucorcel (xenogeneic cells), histology
revealed a focal granuloma. No such cell-mediated immune
response was observed in animals administered with pUTC. A
humoral immune response was also observed in animals
receiving palucorcel. Detectable anti-hUTC IgG antibody levels
were observed in two of six animals. Anti-hUTC was observed
in one animal after 2 weeks, which persisted at 1 month when
this animal was necropsied. Anti-hUTC was observed in a
second animal at 2 months post dose. This animal was one of
two animals observed with a focal granuloma. There were no
detectable antibodies observed in animals receiving pUTC. For
this study, in which human-derived cells were injected into
minipigs, the observed mild immune response suggests a low
likelihood for palucorcel to induce an immune reaction and is
consistent with the low immune response to UTC observed in
previous studies.18,21
This study provides data on the potential adverse events
and other safety sequelae associated with this procedure for
subretinal cell delivery via a suprachoroidal access. Data on
procedure-related adverse events is generally lacking for other
types of cells being evaluated as potential therapies for AMD.
Preclinical studies of these products generally focus on the
safety and tolerability of the cells, rather than the proce-
dure38,39; furthermore, preclinical studies of subretinal cell
delivery have reported the occurrence of retinal perforations
and hemorrhages, though not generally the rates of these
complications.39–41 These findings highlight the need for a
procedure and device with improved safety outcomes for
subretinal delivery of therapeutic products.
Taken together, these results indicate that utilization of a
suprachoroidal approach represents an improvement over
previous surgical approaches, including ab externo and trans-
vitreal routes of administration, for which rates of retinal
detachments and retinal perforations were high and dependent
on surgical expertise.18,23 This approach appears to be less
traumatic, having mitigated the risk of retinal detachment,
retinal traction, and formation of vitreal membrane-like white
opacity observed using previous methods of administration in
the minipig eye, and may be more widely adaptable for a broad
surgical audience.
The device and its procedure were the result of a large
multidisciplinary team, with close interactions throughout the
development process. Future efforts are focused on addressing
the challenges of transferring this new technology to a wide
range of surgeons, and studies assessing the safety and
tolerability of this approach in patients with AMD are
warranted.
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